生物材料介导的向治疗心肌缺血-反损伤的生物材料介导的向治疗
Qiang Luo1, Wei Sun2, Zhibo Li3
1Department of Cardiology, The Second Hospital of Jilin University, 4026 Yatai Street, Changchun 130041, PR China; Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun 130022, PR China.
Biomaterials
|November 17, 2023
概括
功能性生物材料提供了改善的药物输送,以对抗心肌缺血-反损伤 (MIRI) 心脏病发作治疗后. 这些先进材料提高了药物向性,减少了副作用,改善了MIRI患者的治疗结果.
科学领域:
- 生物材料科学 生物材料科学
- 心血管医学 心血管医学
- 药物输送系统 药物输送系统
背景情况:
- 针对急性心肌梗塞的再输血治疗受到矛盾性缺血-再输血损伤 (MIRI) 的限制.
- 针对MIRI的全身药物输送往往由于向和生物可用性差,因此失败.
- 在急性心肌梗塞后,MIRI对死亡率做出了重大贡献.
研究的目的:
- 审查控制药物输送生物材料,以减轻心肌缺血-再输液损伤 (MIRI).
- 探索这些生物材料如何向抗氧化,过载和炎症等机制.
- 讨论临床挑战和这些先进治疗方法的未来应用.
主要方法:
- 对用于MIRI治疗的功能生物材料的文献综述.
- 对药物输送策略的分析,以提高向性和生物可用性.
- 检查生物材料介导的抗氧化,离子过载和炎症的调节.
主要成果:
- 功能生物材料可以优化MIRI的药物输送,提高疗效.
- 这些材料增强了对病理部位的药物向,减少了全身副作用.
- 生物材料通过调节关键损伤路径来促进MIRI治疗.
结论:
- 使用功能生物材料进行控制的药物递送是管理MIRI的有希望的策略.
- 通过生物材料优化药物输送可以克服系统管理的局限性.
- 这些生物材料的进一步临床转化是有必要的,以改善急性心肌梗塞的结果.
相关概念视频
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
170
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
170
01:14Myocarditis III: Medical Management
7
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
7
01:28Acute Coronary Syndrome IV: Interprofessional Care
11
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
11